Pharma Foods International Co. Ltd. (PFI) has announced the achievement of a milestone under its licensing agreement with Mitsubishi Tanabe Pharma Corp. for a new investigational therapeutic antibody for autoimmune diseases.
The generation of anti-citrullinated protein autoantibodies (ACPA) are known key drivers in the pathogenesis of rheumatoid arthritis (RA) and are generated by peptidyl arginine deiminases (PADs).
Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.
Through a global rights agreement with Futuregen Biopharmaceutical Co. Ltd., Abbvie Inc. continues to build its immunology portfolio to help offset losses from Humira as biosimilars tighten their grip on the mega-blockbuster.
Through a global rights agreement with Futuregen Biopharmaceutical Co. Ltd., Abbvie Inc. continues to build its immunology portfolio to help offset losses from Humira as biosimilars tighten their grip on the mega-blockbuster.
Abbvie Inc. and Futuregen Biopharmaceutical (Beijing) Co. Ltd. have signed a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease.
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.
Alchemab Therapeutics Ltd. has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program.
Amgen Inc. is looking to position inebilizumab as the first therapeutic specifically for treating immunoglobulin G4-related disease (IgG4-RD), a rare, immune-mediated condition that can affect multiple organs, after yielding what Leerink Partners analyst David Risinger called “exceptional” phase III results.
RSS
